Company Overview and News

 
Atta Global diversifies into property development

2018-03-07 thestar.com.my
PETALING JAYA: Atta Global Group Bhd is acquiring property company Sungguh Gemilang Development Sdn Bhd for RM12mil to diversify into the property development business.

 
Supportline

2017-12-21 thestar.com.my
ATTA Global Group Bhd has had a good start to the week, pulling strongly up from a downtrend to rise above its short-term descending trend line.

 
Sapura Energy, AirAsia, Ahmad Zaki, Master-Pack, Globetronics, ATTA Global, Vizione, Nexgram, Borneo Oil, Inix, Kerjaya Prospek, Eversafe Rubber and Mulpha International

2017-03-31 theedgemarkets
KUALA LUMPUR (March 31): Based on corporate announcements and news flow today, stocks in focus on Monday (April 3) may include: Sapura Energy Bhd, AirAsia Bhd, Ahmad Zaki Resources Bhd, Master-Pack Group Bhd, Globetronics Technology Bhd, ATTA Global Group Bhd, Vizione Holdings Bhd, Nexgram Holdings Bhd, Borneo Oil Bhd, Inix Technologies Holdings Bhd, Kerjaya Prospek Group Bhd, Eversafe Rubber Bhd and Mulpha International Bhd

 
Stock With Momentum: Atta Global

2017-03-17 theedgemarkets
Atta Global Group Bhd (-ve) SHARES in Atta Global Group Bhd (fundamental: 1.25/3, valuation: 2/3) triggered our momentum algorithm for the first time since October last year. The counter closed four sen or 3.7% higher at RM1.12 yesterday, with 622,400 shares traded. In comparison, its 200-day average volume was only around 48,303 shares.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...